Splenectomy in Patients with Chronic Myeloid Leukemia or Myeloproliferative Diseases: Outcomes, Complications and Prognostic Implications.
Constantine S Tam, Raphael E Pollock, John Manning, Jorge Cortes, Katherine I Lin, Deborah A Thomas, Lingsha Zhou, Hagop Kantarjian, Srdan Verstovsek
Blood | American Society of Hematology | Published : 2007
Abstract The results of splenectomy in 110 patients with myeloproliferative disorders (MPD) were analyzed to determine short-term outcome and complications, and long-term impact on AML transformation and survival. Thirty-one patients had CML in chronic(CP; n=10), accelerated(AP, n=10) or blast phase(BP, n=11); 60 myelofibrosis in CP(n=59) or BP(n=1); 8 CMML; and 11 other MPDs. Median characteristics (range): age 58 yrs (16–85), male 60%, time from diagnosis 6 months (0–187), 2 prior therapies (0–7), performance status 1 (0–3), B-symptoms 70%, transfusion-dependent 50%, spleen 15cm (0–30) below LCM. The number of indications for splenectomy was 1 in 44%, 2 in 40%, and ≥3 in 16%..View full abstract